Company intelligence / Profile preview
Essex Bio-Technology Limited
Chinaessexbio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company has six commercialized biologics marketed in China since 1998. Their bevacizumab ophthalmic injection (EB12-20145P/HLX04-O) met its primary endpoint in a Phase 3 clinical study for the treatment of ophthalmic diseases as announced in April 2025.
- Therapeutic areas
- DermatologyOphthalmologyNeurology
- Modalities
- Genetically engineered therapeutic fibroblast growth factors (FGF)recombinant proteinsmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Shanghai Henlius Biotech, Inc. (for bevacizumab)Dymind Biotechnology Co., Ltd.AC ImmuneMitotechOsteopore
Beyond the preview
Go deeper on Essex Bio-Technology Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Essex Bio-Technology Limited.